Edgar Filing: Anika Therapeutics, Inc. - Form 4

Anika Therap Form 4 February 05,									
FORM	1							PPROVAL	
-	UNITED STAT	ES SECURITIES AI Washington, 1			NGE	COMMISSION	OMB Number:	3235-0287	
Check thi if no long subject to Section 10 Form 4 or		GES IN BENEFICIAL OWNERSHIP OF SECURITIES				burden hou	Expires: January 31, 2005 Estimated average burden hours per response 0.5		
Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section See Instruction 1(b).									
(Print or Type Responses)									
1. Name and A Cheung Sylv	ddress of Reporting Person <u>*</u> ia	2. Issuer Name and Ticker or Trading Symbol Anika Therapeutics, Inc. [ANIK]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (Middle)	3. Date of Earliest Tra	insaction			(Chec	ck all applicable	2)	
32 WIGGIN	S AVENUE	(Month/Day/Year) 02/03/2015				Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer			
(Street) 4. If Amendment, Da Filed(Month/Day/Year)									
BEDFORD,	MA 01730					Form filed by M Person	More than One Re	eporting	
(City)	(State) (Zip)	Table I - Non-De	erivative S	ecuri	ties Ac	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	any		4. Securit onAcquired Disposed (Instr. 3,	ties (A) o of (D	or))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-	
Common Stock (1)	02/03/2015	А	6,675	A	\$0	19,825	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 11 29 ()
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 39.69	02/03/2015		A	13,700	(2)	02/03/2025	Common Stock	13,700	
Stock Option (Right to Buy)	\$ 32.02 (<u>3)</u>	02/03/2015 <u>(4)</u>		A	4,600	(5)	01/27/2024	Common Stock	4,600	

Edgar Filing: Anika Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting of the reader that eas	Director	10% Owner	Officer	Other			
Cheung Sylvia 32 WIGGINS AVENUE BEDFORD, MA 01730			Chief Financial Officer				
Signatures							

Signatures

/s/ Sylvia 02/05/2015 Cheung 02/05/2015 <u>**</u>Signature of Date Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock awards vest in four equal annual installments beginning February 3, 2016.
- (2) The stock options vest in four equal annual installments beginning February 3, 2016.

The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2014, (3) the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 4 and 5.

On February 3, 2015, the Compensation Committee modified the performance measures under the Performance Grant and determined
(4) that under the modified performance measures 100% of the performance grant had been earned, subject to time-based vesting. Please also see notes 3 and 5.

(5) The stock options vest in four equal installments on the following dates: February 3, 2015, January 1, 2016, January 1, 2017 and January 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners

E S (

Edgar Filing: Anika Therapeutics, Inc. - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.